Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析

◆英語タイトル:Oasmia Pharmaceutical AB (OASM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14842
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes apealea (paclical), currently at registration and approval stage, for treating ovarian and metastatic breast cancer; doxophos for treating all doxorubicin indications; and preclinical stage products such as docecal (docetaxel), OAS-19 and KB9520. Its pipeline for animal health includes paccal vet (paklitaxel) and doxophos vet (doxorubicin), currently under phase 2 stage, intended for the treatment of mastocytoma and lymphoma, respectively. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB Key Recent Developments

Mar 01,2019: Oasmia Pharmaceutical: Interim report for the period May 2018 – January 2019
Nov 30,2018: Oasmia Pharmaceutical announce Interim report for the period May – October 2018
Nov 22,2018: Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Sep 25,2018: Annual General Meeting of Oasmia Pharmaceutical held on 25 September 2018

This comprehensive SWOT profile of Oasmia Pharmaceutical AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Oasmia Pharmaceutical AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Oasmia Pharmaceutical AB – Key Information
Oasmia Pharmaceutical AB – Overview
Oasmia Pharmaceutical AB – Key Employees
Oasmia Pharmaceutical AB – Key Employee Biographies
Oasmia Pharmaceutical AB – Key Operational Heads
Oasmia Pharmaceutical AB – Major Products and Services
Oasmia Pharmaceutical AB – History
Oasmia Pharmaceutical AB – Company Statement
Oasmia Pharmaceutical AB – Locations And Subsidiaries
Oasmia Pharmaceutical AB – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Oasmia Pharmaceutical AB – Business Description
Oasmia Pharmaceutical AB – Corporate Strategy
Oasmia Pharmaceutical AB – SWOT Analysis
SWOT Analysis – Overview
Oasmia Pharmaceutical AB – Strengths
Oasmia Pharmaceutical AB – Weaknesses
Oasmia Pharmaceutical AB – Opportunities
Oasmia Pharmaceutical AB – Threats
Oasmia Pharmaceutical AB – Key Competitors

Section 3 – Company Financial Performance Charts

Oasmia Pharmaceutical AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Oasmia Pharmaceutical AB, Key Information
Oasmia Pharmaceutical AB, Key Ratios
Oasmia Pharmaceutical AB, Share Data
Oasmia Pharmaceutical AB, Major Products and Services
Oasmia Pharmaceutical AB, History
Oasmia Pharmaceutical AB, Key Employees
Oasmia Pharmaceutical AB, Key Employee Biographies
Oasmia Pharmaceutical AB, Key Operational Heads
Oasmia Pharmaceutical AB, Other Locations
Oasmia Pharmaceutical AB, Subsidiaries
Oasmia Pharmaceutical AB, Key Manufacturing facilities
Oasmia Pharmaceutical AB, Key Competitors
Oasmia Pharmaceutical AB, SWOT Analysis
Oasmia Pharmaceutical AB, Ratios based on current share price
Oasmia Pharmaceutical AB, Annual Ratios
Oasmia Pharmaceutical AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Oasmia Pharmaceutical AB, Performance Chart
Oasmia Pharmaceutical AB, Ratio Charts

★海外企業調査レポート[Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RainDance Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • University of California Berkeley:製薬・医療:M&Aディール及び事業提携情報
    Summary University of California Berkeley (UC Berkeley), a subsidiary of University of California is an educational university that offers educational programs and research services. The university’s academic programs comprise law and economics program, legal studies; lesbian, gay, bisexual, and tra …
  • Nine Entertainment Co. Holdings Ltd:企業の戦略・SWOT・財務分析
    Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • National Power Corporation:電力:M&Aディール及び事業提携情報
    Summary National Power Corporation (Napocor) is a government owned utility. It develops hydroelectric generation plants; produces power from nuclear, geothermal, and other sources; and transmits electricity across the country. The corporation preserves and protects the dams and watershed. Napocor’s …
  • Damac Real Estate Development Ltd
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Saipem SpA:企業の戦略・SWOT・財務情報
    Saipem SpA - Strategy, SWOT and Corporate Finance Report Summary Saipem SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Shenergy Co., Ltd. (600642):電力:M&Aディール及び事業提携情報
    Summary Shenergy Company, Ltd. (Shenergy) is China-based gas and electricity company. The company is engaged in the construction, investment, operations and management of petroleum, natural gas and electric power. Its electricity projects include hydropower, coal-fired power and thermal power genera …
  • Becton, Dickinson:企業の戦略・SWOT・財務情報
    Becton, Dickinson - Strategy, SWOT and Corporate Finance Report Summary Becton, Dickinson - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Village Super Market, Inc.:企業の戦略・SWOT・財務情報
    Village Super Market, Inc. - Strategy, SWOT and Corporate Finance Report Summary Village Super Market, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Alkermes Plc (ALKS)-製薬・医療分野:企業M&A・提携分析
    Summary Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspen …
  • Cybernet Systems Corporation:企業の戦略・SWOT・財務情報
    Cybernet Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Cybernet Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Renk AG (ZAR):企業の財務・戦略的SWOT分析
    Renk AG (ZAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Vanderbilt University:製薬・医療:M&Aディール及び事業提携情報
    Summary Vanderbilt University (Vanderbilt) is a medical and research university that provides professional degrees. The university offers graduate and undergraduate degrees in the fields of engineering, music, liberal arts and sciences, education and human development. It provides services such as c …
  • Altor BioScience Corp-製薬・医療分野:企業M&A・提携分析
    Summary Altor BioScience Corp (Altor BioScience) is a clinical stage biopharmaceutical company that discovers, develops and commercializes immunotherapeutic products. The company’s pipeline products include ALT-801, ALT-836, and ALT-803. Its technologies are soluble t-cell antigen receptor, inhibito …
  • Hubbell Incorporated:企業の戦略・SWOT・財務情報
    Hubbell Incorporated - Strategy, SWOT and Corporate Finance Report Summary Hubbell Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Owen Mumford Ltd:企業の戦略的SWOT分析
    Owen Mumford Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Mack-Cali Realty Corp (CLI):企業の財務・戦略的SWOT分析
    Mack-Cali Realty Corp (CLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • McLean Electric Cooperative Inc:企業の戦略的SWOT分析
    McLean Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Cardiatis SA:製品パイプライン分析
    Summary Cardiatis SA (Cardiatis) is a medical device company that develops a multilayer technology platform for endovascular aneurysm. The company offers a three dimensional multilayer braided stent system for endovascular aneurysm repair. Its multilayer flow modulator include aortic, peripheral, bi …
  • SGD S.A.:企業の戦略・SWOT・財務情報
    SGD S.A. - Strategy, SWOT and Corporate Finance Report Summary SGD S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆